GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » Debt-to-EBITDA

Genesystem Co (XKRX:363250) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genesystem Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genesystem Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Genesystem Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Genesystem Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ₩-759.0 Mil. Genesystem Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genesystem Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:363250' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.37   Med: -0.62   Max: 1.16
Current: -0.84

During the past 5 years, the highest Debt-to-EBITDA Ratio of Genesystem Co was 1.16. The lowest was -1.37. And the median was -0.62.

XKRX:363250's Debt-to-EBITDA is ranked worse than
100% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79 vs XKRX:363250: -0.84

Genesystem Co Debt-to-EBITDA Historical Data

The historical data trend for Genesystem Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genesystem Co Debt-to-EBITDA Chart

Genesystem Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.17 -1.37 1.16 -0.62 -0.62

Genesystem Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.57 -0.48 -0.89 -

Competitive Comparison of Genesystem Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Genesystem Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genesystem Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genesystem Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genesystem Co's Debt-to-EBITDA falls into.



Genesystem Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genesystem Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1380.502 + 3107.177) / -7233.609
=-0.62

Genesystem Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -758.98
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Genesystem Co  (XKRX:363250) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genesystem Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genesystem Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genesystem Co (XKRX:363250) Business Description

Traded in Other Exchanges
N/A
Address
200-9, Techno 2-ro, Yuseong-gu, Daejeon, KOR, 34028
Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.

Genesystem Co (XKRX:363250) Headlines

No Headlines